LEXINGTON, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that Rhode Island Hospital, the principal teaching hospital of The Warren Alpert Medical School of Brown University, the University of Alabama at Birmingham Hospital and The Statens Serum Institut in Denmark are among the first adopters of its T2Candida® sepsis diagnostic. Run on the T2Dx Instrument, the T2Candida Panel detects Candida, the most lethal cause of sepsis. T2 Biosystems provides the first and only sepsis diagnostic that provides species specific results and does not require blood culture, delivering accurate results in three-to-five hours compared to two-to-six days for a blood culture.

"We are pleased to be working with such leading institutions that are implementing our platform with the goal of improving and saving the lives of patients while reducing the cost of treating sepsis," said John McDonough, chief executive officer of T2 Biosystems. "These partnerships are an important first step towards us realizing our vision of making a difference in the management of sepsis for patients, hospitals and healthcare overall."

"Sepsis is a deadly disease that requires the best experts, care and technology to manage patients effectively, and these three pillars form the basis of any commitment to deliver the best care that sepsis patients can receive. Rhode Island Hospital is optimistic that the integration of T2Candida into our process for addressing sepsis will improve our ability to diagnose and treat patients quickly and accurately – which can make all the difference in improving outcomes and saving lives," said Louis Rice, M.D., chair of the Department of Medicine at The Warren Alpert Medical School and chief of medicine at Rhode Island and The Miriam hospitals. "We hope that T2Candida will make a positive difference with patients and improve the overall treatment process while lowering healthcare costs."

About Sepsis

Sepsis is one of the leading causes of death in the U.S. and the most expensive hospital-treated condition, with costs to the healthcare system exceeding $20 billion each year, according to the U.S. Department of Health and Human Services. The T2Candida Panel uses T2 magnetic resonance (T2MR) technology to detect the presence of five clinically relevant species of Candida, the most lethal form of common blood stream infections that cause sepsis, directly from a patient's blood sample in approximately three-to-five hours, enabling physicians to make timely treatment decisions to reduce adverse outcomes, patient mortality, and costs.

About The T2Candida Panel

The T2Candida Panel is the first sepsis pathogen diagnostic that provides species-specific results in three-to-five hours without the need for blood culture, which can take up to six days to provide a result. The rapid detection of Candida enables physicians to provide targeted treatment quickly, and research has shown this can reduce a positive sepsis patient's length of stay in the hospital by almost nine days at a cost savings of approximately $26,887. A rapid negative result can prevent unnecessary administration of antimicrobials, further reducing costs. In addition, a rapid negative result can prevent or reduce antimicrobial resistance, which the Centers for Disease Control and Prevention has designated a serious threat.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as supplemented or amended from time to time under "Item 1A.—Risk Factors" in our Quarterly Reports on Form 10-Q, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

CONTACT: Media Contact:
         Susan Heins, Pure Communicationssusan@purecommunicationsinc.com
         864.286.9597

         Investor Contact:
         Matt Clawson, Pure Communicationsmatt@purecommunicationsinc.com
         949-370-8500